For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.

Immunotherapy in Glioblastoma.

TitleImmunotherapy in Glioblastoma.
Publication TypeJournal Article
Year of Publication2018
AuthorsWilcox JA, Ramakrishna R, Magge R
JournalWorld Neurosurg
Volume116
Pagination518-528
Date Published2018 Aug
ISSN1878-8769
KeywordsAntibodies, Monoclonal, Combined Modality Therapy, Dendritic Cells, Glioblastoma, Humans, Immunotherapy, T-Lymphocytes
Abstract

Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor vaccinations from both dendritic cell and tumor peptide components, adoptive transfer of supercharged and durable T lymphocytes, and generation of oncolytic viruses. Although immunotherapy has already demonstrated efficacy for a variety of other malignancies, its efficacy in glioblastoma is still unclear. Identifying predictive biomarkers and improving the management of immune-related adverse effects will help to realize the full potential of these therapies.

DOI10.1016/j.wneu.2018.04.020
Alternate JournalWorld Neurosurg
PubMed ID30049046